Journal article
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Authors
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S
Journal
LANCET, Vol. 388, No. 10056, pp. 2128–2141
Publisher
ELSEVIER SCIENCE INC
Publication Date
October 29, 2016
DOI
10.1016/S0140-6736(16)31322-8
ISSN
0140-6736